Heterozygote advantage for HLA class-II type in hepatitis B virus infection
Mark Thursz(Imperial College Healthcare NHS Trust), Adrian V. S. Hill(Jenner Institute), Brian Greenwood(London School of Hygiene & Tropical Medicine), Howard C. Thomas(St Mary's Hospital)
Cited by 319
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION
|The Lancet|1989|1.2k
Vaccine-induced escape mutant of hepatitis B virus
|The Lancet|1990|1.1k
Cholangiocarcinoma
|The Lancet|2005|1.1k
Viral dynamics in hepatitis B virus infection.
|Proceedings of the National Academy of Sciences|1996|1k